CORDIS
EU research results

CORDIS

English EN
Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975

Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975

Objective

APOEɛ4 has long been known as a risk factor of LOAD, yet the biological mechanisms through which it acts remain largely unknown and affect both the vasculature and the brain. This complexity and pleiotropic influence demands an integrated hypothesis-free approach to embark on a fundamental study of the gene, the phenotype and modulation by other risk factors. ADAPTED proposes to leverage extreme genotypes from consortium cohorts dating back more than 25 years to generate, and use existing, lines of human induced pluripotent stem cells (iPSC). These cells, with blood cells, will form the backbone of the research programme. We will differentiate them to the most relevant cells for APOE and AD studies and with gene editing create bespoke homozygote ɛ3 and ɛ2 cells for a highly focussed effort on APOE biology. A series of experiments including neuron-astrocyte and macrophage-endothelium co-culture and Organ on a Chip models combined with state-of-the-art omics including quantitative proteomics assays will generate data for rigorous integrated analysis to uncover new signalling pathways related to APOE. Lipid homeostasis, endocytosis, metabolism and immune systems pathways will be investigated in a broad approach. The findings are expected to lead to identification of new treatment approaches and blood based AD signatures with a temporal dimension from the earliest stages of risk identification and progression through MCI to AD. Testing and validation of biomarkers will be performed by examining their influence and predictive capacity in a longitudinal ADAPTED cohort harmonised using a combination of approaches for marker and diagnostic consistency. The impact of this work can be expected to include seminal new finding to illuminate the research path towards new diagnostics and therapies to attenuate the rising tide of suffering from AD. The vision is a follow on with clinical proof of concept validating utility of the results within two years of the end of ADAPTED.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FUNDACIO ACE

Address

Marques De Sentmenat 57
08014 Barcelona

Spain

Activity type

Research Organisations

EU Contribution

€ 333 757

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

ABBVIE DEUTSCHLAND GMBH & CO KG

Germany

BIOGEN IDEC LIMITED

United Kingdom

CAEBI BIOINFORMATICA SOCIEDAD LIMITADA

Spain

EU Contribution

€ 282 062

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 688 476

DC BIOSCEINCES LTD

United Kingdom

EU Contribution

€ 186 514

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 420 500

JANSSEN PHARMACEUTICA NV

Belgium

KITE INNOVATION (EUROPE) LIMITED

United Kingdom

EU Contribution

€ 37 912,66

UNIVERSITEIT LEIDEN

Netherlands

EU Contribution

€ 470 677

MIMETAS BV

Netherlands

EU Contribution

€ 305 102

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 429 850

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 244 812

MODUS RESEARCH AND INNOVATION LIMITED

United Kingdom

EU Contribution

€ 110 337,34

Project information

Grant agreement ID: 115975

Status

Ongoing project

  • Start date

    1 October 2016

  • End date

    30 September 2019

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 6 796 740

  • EU contribution

    € 3 510 000

Coordinated by:

FUNDACIO ACE

Spain